Your browser doesn't support javascript.
loading
Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients
Anwar M Hashem; Abdullah Algaissi; Sarah A Almahboub; Mohamed A Alfaleh; Turki S Abujamel; Sawsan S Alamri; Khalid A Alluhaybi; Haya I Hobani; Rahaf H AlHarbi; Reem M Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K Alharbi; Rowa Y Alhabbab; Ahdab A AlSaieedi; Wesam H Abdulaal; Abdullah Bukhari; Afrah A AL-Somali; Fadwa S Alofi; Asim A Khogeer; Arnab Pain; Almohanad A Alkayyal; Naif AM Almontashiri; Ahmad B Mahmoud; Xuguang Li.
Afiliação
  • Anwar M Hashem; King Abdulaziz University
  • Abdullah Algaissi; Jazan University
  • Sarah A Almahboub; King Abdulaziz University
  • Mohamed A Alfaleh; King Abdulaziz University
  • Turki S Abujamel; King Abdulaziz University
  • Sawsan S Alamri; King Abdulaziz University
  • Khalid A Alluhaybi; King Abdulaziz University
  • Haya I Hobani; King Abdulaziz University
  • Rahaf H AlHarbi; King Abdulaziz University
  • Reem M Alsulaiman; King Abdulaziz University
  • M-Zaki ElAssouli; King Abdulaziz University
  • Sharif Hala; King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah,
  • Naif K Alharbi; King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh,
  • Rowa Y Alhabbab; King Abdulaziz University
  • Ahdab A AlSaieedi; King Abdulaziz University
  • Wesam H Abdulaal; King Abdulaziz University
  • Abdullah Bukhari; Imam Mohammed Ibn Saud Islamic University, Riyadh, Saudi Arabia
  • Afrah A AL-Somali; Infectious Diseases Department, King Abdullah medical complex, Jeddah, Saudi Arabia
  • Fadwa S Alofi; Infectious Diseases Department, King Fahad Hospital, Almadinah Almunwarah, Saudi Arabia
  • Asim A Khogeer; Plan and Research Department, General Directorate of Health Affairs Makkah Region, Ministry of Health, Makkah, Saudi Arabia
  • Arnab Pain; King Abdullah University for Science and Technology
  • Almohanad A Alkayyal; University of Tabuk, Tabuk, Saudi Arabi
  • Naif AM Almontashiri; Taibah University, Almadinah Almunwarah, Saudi Arabia
  • Ahmad B Mahmoud; Taibah University, Saudi Arabia
  • Xuguang Li; Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Products and Food Branch (HPFB), Health Canada and WHO Collaborating Center
Preprint em Inglês | medRxiv | ID: ppmedrxiv-20198309
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
The Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Immunological surrogate markers, in particular antigen-specific responses, are of unquestionable value for clinical management of patients with COVID-19. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized patients with RT-PCR confirmed COVID-19 infection. Our data show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Notably, anti-S and -N IgG, peaked 20-40 day after disease onset, and were still detectable for at least up to 70 days, with nAbs observed during the same time period. Moreover, nAbs titers were strongly correlated with IgG antibodies. Significantly higher levels of nAbs as well as anti-S1 and N IgG and IgM antibodies were found in patients with more severe clinical presentations, patients requiring admission to intensive care units (ICU) or those with fatal outcomes. Interestingly, lower levels of antibodies, particularly anti-N IgG and IgM in the first 15 days after symptoms onset, were found in survivors and those with mild clinical presentations. Collectively, these findings provide new insights into the characteristics and kinetics of antibody responses in COVID-19 patients with different disease severity.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...